We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
This certification will open new markets for the Kwality Pharma
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Subscribe To Our Newsletter & Stay Updated
